411 related articles for article (PubMed ID: 12395976)
1. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression.
Hedman M; Neuvonen PJ; Neuvonen M; Holmberg C; Antikainen M
Clin Pharmacol Ther; 2004 Jan; 75(1):101-9. PubMed ID: 14749696
[TBL] [Abstract][Full Text] [Related]
4. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses.
Olbricht C; Wanner C; Eisenhauer T; Kliem V; Doll R; Boddaert M; O'Grady P; Krekler M; Mangold B; Christians U
Clin Pharmacol Ther; 1997 Sep; 62(3):311-21. PubMed ID: 9333107
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A.
Regazzi MB; Iacona I; Campana C; Gavazzi A; Viganò M; Perani G
Transplant Proc; 1994 Oct; 26(5):2644-5. PubMed ID: 7940825
[No Abstract] [Full Text] [Related]
7. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients.
Penson MG; Fricker FJ; Thompson JR; Harker K; Williams BJ; Kahler DA; Schowengerdt KO
J Heart Lung Transplant; 2001 Jun; 20(6):611-8. PubMed ID: 11404165
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Neuvonen PJ; Kantola T; Kivistö KT
Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
[TBL] [Abstract][Full Text] [Related]
9. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia.
Hedman M; Neuvonen PJ; Neuvonen M; Antikainen M
Clin Pharmacol Ther; 2003 Aug; 74(2):178-85. PubMed ID: 12891228
[TBL] [Abstract][Full Text] [Related]
11. Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients.
Sud K; Singh B; Krishna VS; Thennarasu K; Kohli HS; Jha V; Gupta KL; Sakhuja V
Nephrol Dial Transplant; 1999 Jul; 14(7):1698-703. PubMed ID: 10435879
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia.
Almutairi F; Peterson TC; Molinari M; Walsh MJ; Alwayn I; Peltekian KM
Liver Transpl; 2009 May; 15(5):504-8. PubMed ID: 19399742
[TBL] [Abstract][Full Text] [Related]
13. The interaction of diltiazem with lovastatin and pravastatin.
Azie NE; Brater DC; Becker PA; Jones DR; Hall SD
Clin Pharmacol Ther; 1998 Oct; 64(4):369-77. PubMed ID: 9797793
[TBL] [Abstract][Full Text] [Related]
14. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin.
Seipelt IM; Crawford SE; Rodgers S; Backer C; Mavroudis C; Seipelt RG; Pahl E
J Heart Lung Transplant; 2004 Mar; 23(3):317-22. PubMed ID: 15019641
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
Hunninghake DB; Knopp RH; Schonfeld G; Goldberg AC; Brown WV; Schaefer EJ; Margolis S; Dobs AS; Mellies MJ; Insull W
Atherosclerosis; 1990 Nov; 85(1):81-9. PubMed ID: 2126437
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
Renders L; Mayer-Kadner I; Koch C; Schärffe S; Burkhardt K; Veelken R; Schmieder RE; Hauser IA
Nephrol Dial Transplant; 2001 Jan; 16(1):141-6. PubMed ID: 11209008
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase.
Pan HY
Eur J Clin Pharmacol; 1991; 40 Suppl 1():S15-8. PubMed ID: 1904355
[TBL] [Abstract][Full Text] [Related]
19. The effects of pravastatin on hyperlipidemia in renal transplant recipients.
Yoshimura N; Oka T; Okamoto M; Ohmori Y
Transplantation; 1992 Jan; 53(1):94-9. PubMed ID: 1733092
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
